Results 41 to 50 of about 3,437 (189)

Multifactorial Perspective for Greening Solid‐Phase Peptide Synthesis: Rigid Polyacrylate Macroporous Resin in Combination with Green Solvents

ChemSusChem, Volume 19, Issue 7, 14 April 2026.
A rigid, non‐swelling polyacrylate resin enables greener solid‐phase peptide synthesis by allowing various green solvents during the peptide synthesis and significantly reduced process mass intensity without compromising peptide synthesis efficiency/purity.
Sikabwe Noki, Ashish Kumar, Cheng Zhang, Alesandra Basso, Simona Serban, Xiaokang Kou, Yanjun Li, Anamika Sharma, Beatriz G. de la Torre, Fernando Albericio   +9 more
wiley   +1 more source

Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes

, 2009
Background: Enfuvirtide is active against isolates from different HIV-1 subtypes. In vitro and in vivo studies reveal that resistance mutations are primarily found within the region spanning amino acid 36-45 of gp41.
Van Wijngaerden, Eric, Eric Van Wijngaerden, Yoeri Schrooten, De Wit, Stéphane, Stéphane De Wit, Covens, Kris, Kristel Van Laethem, Vandamme, Anne-Mieke, Kabamba Kabeya, Dekeersmaeker, Nathalie, Anne-Mieke Vandamme, Van Laethem, Kristel, Kabeya, Kabamba, Kris Covens, Schrooten, Yoeri, Nathalie Dekeersmaeker   +15 more
core   +1 more source

Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. [PDF]

PLoS ONE, 2012
Albuvirtide (ABT) is a 3-maleimimidopropionic acid (MPA)-modified peptide HIV fusion inhibitor that can irreversibly conjugate to serum albumin. Previous studies demonstrated its in vivo long half-life and potent anti-HIV activity.
Huihui Chong, Xue Yao, Chao Zhang, Lifeng Cai, Sheng Cui, Youchun Wang, Yuxian He   +6 more
doaj   +1 more source

A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile

Pharmaceuticals, 2022
Recently, a series of highly effective peptide- or protein-based HIV fusion inhibitors have been identified. However, due to their short half-life, their clinical application is limited.
Wei Xu, Zhe Cong, Qianyu Duan, Qian Wang, Shan Su, Rui Wang, Lu Lu, Jing Xue, Shibo Jiang   +8 more
doaj   +1 more source

Relapse of Intravenous Drug Use Triggered by Enfuvirtide, a Parenteral Antiretroviral Medication

, 2012
Fuzeon (R) (enfuvirtide; Hoffmann-LaRoche, Nutley, NJ) is a parenteral medication prescribed to antiretroviral-experienced HIV patients. Clinicians are frequently concerned when prescribing enfuvirtide to former drug addicts because of the risk of ...
Avelino-Silva, Vivian Iida, Gallafrio Novaes, Christina Terra   +1 more
core   +1 more source

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia [PDF]

, 2003
The T-20 vs. Optimized Regimen Only Study 2 (TORO 2) compared the efficacy and safety of 24 weeks of treatment with the fusion inhibitor enfuvirtide in combination with an optimized background antiretroviral regimen with the efficacy and safety of the ...
Salgo, Miklos, Lazzarin, A., Lange, J.M.A., Clotet, Bonaventura, Katlama, Christine, Salgo, M., Lange, Joep, Wat, Cynthia, Delfraissy, JF, DeMasi, R, Neslon, M, Clotet, B., Clotet, B, Lazzarin, Adriano, Lazzarin, A, Katlama, C, Stellbrink, H.J., Nelson, M., Wat, C., Delfraissy, J.F., Drobnes, C., Huson, L., Katlama, C., Cooper, David, Nelson, Mark, Delehanty, John, Wat, C, Reynes, J., Cooper, D., Delehanty, J., Reynes, J, Drobnes, C, Saldo, M, TORO-2 study group, -, DeMasi, Ralph, Ende, Marchina, Reynes, Jacques, Arastéh, Keikawus, Stellbrink, HJ, Drobnes, Claude, Stellbrink, Hans-Jürgen, Huson, L, Arasteh, K, De Masi, R., Cooper, D, Delehanty, J, Huson, Les, Lange, J, Arasteh, K., Delfraissy, Jean-François   +49 more
core   +1 more source

Valproic acid and HIV-1 latency: beyond the sound bite

Retrovirology, 2005
A recent publication in Lancet by Dr. David Margolis and colleagues raised the prospect that HIV infection may be curable. In this pilot study, which received much attention from the press, Dr.
Smith Stephen M
doaj   +1 more source

Membrane Fusion‐Inspired Nanomaterials: Emerging Strategies for Infectious Disease and Cancer Diagnostics

Advanced Healthcare Materials, Volume 15, Issue 6, 9 February 2026.
Membrane fusion‐inspired nanomaterials offer transformative potential in diagnostics by mimicking natural fusion processes to achieve highly sensitive and specific detection of disease biomarkers. This review highlights recent advancements in nanomaterial functionalization strategies, signal amplification systems, and stimuli‐responsive fusion designs,
Sojeong Lee, Khulan Nyamzaya, Jueun Han, Yejin Song, Jihee Lee, Jung Hyun Jo, Seungmin Bang, Eun‐Kyung Lim, Seungjoo Haam, Eunjung Kim   +9 more
wiley   +1 more source

Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development

, 2004
The peptidic antiretroviral enfuvirtide (Fuzeon) is the first clinically approved antiviral fusion inhibitor and the first antiretroviral that must routinely be administered parenterally.
David A Cooper, Cooper, David A., Lange, Joep M. A., Joep MA Lange   +3 more
core   +1 more source

Expediting Glycospace Exploration: Therapeutic Glycans via Automated Synthesis

Angewandte Chemie, Volume 137, Issue 13, March 24, 2025.
The construction of well‐defined carbohydrates constitutes a nexus in glycoscience, but few conceptual paradigms have shaped the field as much as automated glycan synthesis. This minireview describes the structural diversity and function of glycans generated by automated glycan synthesis platforms over the last five years.
James Suri, Ryan Gilmour
wiley   +2 more sources